Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
To the Editor: Brodalumab, a human monoclonal antibody that binds to interleukin (IL)-17RA (receptor subunit utilized by pro-inflammatory cytokines IL-17A, IL-17F, and IL-17A/F), has been shown at doses of 210 mg every 2 weeks to be superior to ustekinumab and placebo in treating moderate-to-severe plaque psoriasis in 2 large phase 3 studies: AMAGINE-2 and AMAGINE-3. 1, 2 Time to achieve significant improvements in psoriasis disease severity is an important aspect of patient treatment and education. Our objective was to evaluate the speed of action of brodalumab with the use of data from AMAGINE-2 and AMAGINE-3.
Detailed study designs are reported elsewhere. 2 In these analyses, efficacy assessments included median times for 25% of patients to achieve Psoriasis Area and Severity Index (PASI) 75, static Physician's Global Assessment (sPGA) success (score 0/1), and median times to achieve 25%, 50%, and 75% reductions in baseline PASI. Estimated times for 25% of patients to achieve PASI 75 were 2.1 (95% confidence interval [CI], 2.0-2.3) weeks for brodalumab and 4.8 (95% CI, 4.5-5.1) weeks for ustekinumab (Fig 1, A) ; times for 25% of patients to achieve sPGA success were 2.5 (95% CI, 2.4-2.6) weeks and 5.6 (95% CI, 5.2-6.0) weeks, respectively (Fig 1, B) . Differences in speed of efficacy between brodalumab and ustekinumab were evident as early as week 1, whereas 3.5% (95% CI, 2.5-4.7) of brodalumab-treated patients achieved sPGA success and PASI 75 in individual independent assessments, compared with 0.7% (sPGA success; 95% CI, 0.2-1.7) and 0.2% (PASI 75; 95% CI, 0.0-0.9) of ustekinumab-treated patients (PASI 75 and sPGA success, both P \.001). By week 12, 85.7% (95% CI, 83.6-87.6) and 79.1% (95% CI, 76.8-81.4) of patients treated with brodalumab achieved PASI 75 and sPGA success, respectively, compared with 69.7% (95% CI, 65.8-73.3) and 59.1% (95% CI, 55.0-63.0) of patients treated with ustekinumab (both P \.001).
Improvement in baseline PASI over time also revealed rapid and sustained brodalumab efficacy. Median time to achieve a 75% improvement in baseline PASI (PASI 75) was estimated at 4.2 weeks for brodalumab and 9.4 weeks for ustekinumab (Fig 2) . Furthermore, times needed to achieve 25% and 50% median improvement in baseline PASI were 0.8 [95% CI, 0.8-0.8] and 1.8 [95% CI, 1.8-1.9] weeks, respectively, for brodalumab compared with 1.8 (95% CI, 1.7-2.0) and 4.5 (95% CI, 4.2-4.8) weeks for ustekinumab (all P \ .0001).
Our data suggest that brodalumab 210 mg every 2 weeks provides rapid improvement in disease severity of moderate-to-severe plaque psoriasis. In addition, comparative data suggest that brodalumab may have the most rapid onset of action of any biologic therapy used in psoriasis (2.1 weeks versus 2.4 weeks for ixekizumab, 3 3.0 weeks for high-dose secukinumab), 4 when using the measure of the time required for 25% of patients to achieve PASI 75. Brodalumab also demonstrates shorter time to achieve a 50% improvement in baseline PASI (1.8 weeks) compared with that reported for ixekizumab (1.9 weeks) 5 or high-dose secukinumab (3 weeks). 4 In addition, the median time to achieve PASI 75 with brodalumab in our study was 4.2 weeks compared with 4.4 weeks, previously reported for ixekizumab. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis
To the Editor: Quinacrine, a compounded antimalarial, has been used for patients intolerant or unresponsive to hydroxychloroquine. In March 2016, the Pharmacy Compounding Advisory Committee raised safety concerns about quinacrine-associated aplastic anemia. In addition, the Office of New Drugs advised that although quinacrine might be safe at the 100 mg/ day dose prescribed for rheumatic skin diseases, generalists might prescribe this drug at higher doses and for alternative indications that have yet to be formally studied. As a consequence, this orphan drug may no longer be compounded and might become effectively unavailable with a prescription, requiring an Investigational New Drug, institutional review board approval, patient consent, and toxicity reporting. To evaluate the need for continued access, we surveyed providers at various institutions to determine their quinacrine prescribing practices. Two rheumatologic skin disease specialists (Drs Costner and Bangert) from Texas estimated having seen 96 and 30 patients on quinacrine within the last year but . Median time to 75%, 50%, and 25% reduction in mean PASI was estimated from bootstrap samples with the use of linear interpolation between time points. Multiple imputation was used to impute missing data with 3 imputed datasets.
